The controversy sparked by the availability of proven weight-loss drugs will never subside. He will continue to interact and interact, between praising and denouncing, between willing and rejecting, and between reassuring and apprehensive. This prompted the World Health Organization to delve into what is reported about the capabilities of drugs such as “Wegovi”, “Ozimbik” and “Monjaro”. Francisco Branca, Director of the WHO’s Nutrition Department, described these drugs as “not a magic bullet” that could address the rapidly rising rates of obesity and obesity around the world. Branca revealed that the organization is currently conducting the first review in 20 years of its guidance on how to manage obesity. It will start with guidelines for treating obesity in children and adolescents, and then move on to update its guidance for adults with obesity. The World Health Organization, developed these guidelines in the year 2000, to be a plan that can be used by countries that do not have sufficient resources to develop and implement their own national plans. The organization asked the Mario Negri Institute for Pharmaceutical Research, which is based in Milan, Italy, to evaluate the evidence on the use of all classes of medicines in children and adolescents, from the old drugs available to combat weight gain to the newest innovations of scientists, such as Wigovi, Monjaro and Ozimbik. . Franca warned that what is reported about modern medicines as a solution to the problem is not true. And he believed – in an interview in London with Reuters – that anti-obesity drugs are important, but they must be part of a comprehensive approach. “It’s not a magic bullet,” he says. He explained that other measures, including diet and exercise, remain vital to help control obesity. He added that the latest statistics of the World Health Organization indicate that the percentage of children and adolescents who suffer from obesity, between the ages of 5 and 19 years, increased from 4% in 1975 to more than 18% in 2016. The current number of individuals in this category is more than 340 million people around the world. Monjaro, Igovi, and Ozimbik were originally developed to treat type 2 diabetes. But scientists said, they finally discovered its ability to reduce body weight mass by up to 15%, which aroused widespread interest from the public, investors, and celebrities in Hollywood. These drugs are known as GLP-1, and it is a substance that is taken by injection once a week, and its action is based on affecting the hunger signals issued by the brain, so that the patient’s desire to eat decreases, and he feels full for a longer period. However, one of the main problems with these drugs is that they must be taken for life! Any interruption will lead to a return to weight gain. It is noteworthy that the drug Wagovi, which was invented by the Danish company Novo Nordisk, is licensed in the United States and Europe as valid for weight loss. Monjaro, developed by the US pharmaceutical company Eli Lilly, is expected to receive approval from the US Food and Drug Administration later this year. It is expected that the demand for these drugs will reach sales of about $ 100 billion during the next ten years. It is expected that the number of drugs aimed at treating obesity will reach no less than 10 drugs. At the same time, the responsible medical authorities in the United States began to reconsider their guiding controls related to the treatment of obesity and obesity, so that specific directions are reached on how to use the Wegovi, Monjaro, and Ozimbik drugs, amid a division between specialists who believe that they can be used without restriction, and others who believe that The priority of their use should be limited to patients with chronic conditions, such as diabetes and heart disease, which worsen with increasing body weight. The American Academy of Pediatrics clarified the use of these drugs on children from the age of 12 years and over; Although there is not yet enough data on the effects of its long-term use. Branca said the new guidelines for treating obesity in children and adolescents are expected to be issued by the end of 2023.
Zeeland Pharma and Boehringer Ingelheim announced, at a conference in Frankfurt, Germany, that the data confirmed the success of a drug they developed to combat obesity and obesity in reducing body weight by 14.9% after 46 weeks of taking it in the scope of the second phase of a clinical trial in this regard. The two companies said they are in contact with regulators to allow them to conduct a third and final phase of clinical trials. Thus, these two companies will join a growing number of pharmaceutical companies that will dominate the obesity and obesity medicine market during the next decade. There could be as many as 10 competing drugs, executives and financial analysts said. Its sales during the aforementioned period may reach about $100 billion in the United States alone.
Sleep… you have to increase it.. for these reasons
In 2017, the Nobel Prize was awarded to three scientists whose research found that humans have a network of genes whose job it is to set the timing and release of proteins that determine daily cycles of rest and activity. Scientists now believe that sleep is the key to good health, and it is necessary to get plenty of it. And the American Heart Association recommended that its members of doctors need to inform their patients that the number of hours they sleep is as important as the need to check blood pressure, and follow the diet and exercise. However, in their ordinary lives, people resist sleeping. Many people used to expel drowsiness by drinking stimulant drinks, such as coffee and tea. Others prefer to work all night, only to spend the day sleeping. Scientists say, it must be realized that the timing and number of hours of sleep is very important. Therefore, it is necessary to take into account these aspects, because new research has confirmed that rhythms within the body play an important role in the response to cancer treatment drugs. Researchers have unanimously agreed since ancient times that man was created with genes that prepare him to be active during the daytime hours, and to rest during the night. Genes for timing are thought to be found throughout the body, including hormones, blood pressure, blood sugar, and body temperature. One of the wonders of God’s creation of man is that he is genetically programmed to feel more hungry during the evening times, so that he is forced to eat to provide the body with calories that the body can use during the sleep period. It is also programmed to feel less hungry when it wakes up in the morning, so that when it goes out hunting in the morning it can use its nightly calories to provide for its next meal. Recent research concluded that the timing devices on which man was created represent a regular rhythm over the twenty-four hours every day. It is programmed during daylight hours and during dark hours. Each affects different parts of the body. Some of these timers work best during a specific time of day. There are kidneys – for example – that perform their best work during the day. But the night is very important for brain activity. Waste filtering activity peaks during the day and is very low at night. The rhythm of the hormones secreted by the kidneys to regulate blood pressure and the production of red blood cells takes place during the day and stops at night. It is believed that between 10% and 60% of people suffer from a lack of sleep, according to estimates from the American Psychological Association. Scientists say that excessive sleep is a problem that indicates health defects. They say that any sleep that exceeds 9 hours delays the examination. According to the American National Sleep Foundation, the number of hours of sleep for people between the ages of 18 and 64 years is between 7 and 9 hours per day; For older people, 7 to 8 hours a day.